DBV Technologies (NASDAQ:DBVT) Shares Gap Down - What's Next?

Key Points

• Shares gapped down: DBV opened at $22.37 after closing $23.54 and was last at $22.10, down about 5.4% on roughly 74,948 shares traded.
• Analyst sentiment tilted positive: The consensus is a "Moderate Buy" with a $38.25 price target, and several brokers recently raised targets to the $40–$48 range (e.g., Citizens Jmp to $45, Cantor Fitzgerald to $48).
• Significant insider selling: Major shareholder Bpifrance Epic sold 1.29M shares (a 15% reduction) and insiders have sold ~3.37M shares in the past 90 days, while institutional investors still own about 71.7% of the stock.

DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report)'s share price gapped down prior to trading on Wednesday . The stock had previously closed at $23.54, but opened at $22.37. DBV Technologies shares last traded at $22.10, with a volume of 74,948 shares.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on DBVT. Citizens Jmp boosted their price objective on shares of DBV Technologies from $21.00 to $45.00 and gave the stock a "market outperform" rating in a research report on Wednesday, December 17th. Cantor Fitzgerald set a $48.00 price objective on shares of DBV Technologies in a report on Wednesday, December 17th. Wall Street Zen upgraded DBV Technologies from a "sell" rating to a "hold" rating in a report on Sunday, February 8th. HC Wainwright set a $40.00 price target on shares of DBV Technologies in a research report on Thursday, December 18th. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of DBV Technologies in a research report on Monday, December 29th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $38.25.

DBV Technologies Trading Down 5.4%

The stock has a market cap of $1.24 billion, a P/E ratio of -4.32 and a beta of -0.97. The company has a 50 day simple moving average of $21.08 and a 200 day simple moving average of $16.36.

Insider Buying and Selling

In other DBV Technologies news, major shareholder Bpifrance Epic sold 1,292,103 shares of DBV Technologies stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $4.19, for a total transaction of $5,413,911.57. Following the transaction, the insider owned 7,303,369 shares of the company's stock, valued at $30,601,116.11. This trade represents a 15.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders have sold 3,369,627 shares of company stock valued at $15,489,908. Company insiders own 1.44% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Allworth Financial LP bought a new stake in shares of DBV Technologies in the 4th quarter worth approximately $32,000. Royal Bank of Canada purchased a new stake in DBV Technologies in the fourth quarter valued at about $34,000. New York State Common Retirement Fund purchased a new stake in shares of DBV Technologies during the third quarter worth about $34,000. GAMMA Investing LLC increased its holdings in shares of DBV Technologies by 38.4% during the fourth quarter. GAMMA Investing LLC now owns 2,680 shares of the company's stock valued at $51,000 after acquiring an additional 744 shares in the last quarter. Finally, Truvestments Capital LLC lifted its stake in shares of DBV Technologies by 71.3% during the fourth quarter. Truvestments Capital LLC now owns 3,892 shares of the company's stock worth $75,000 after buying an additional 1,620 shares during the period. Institutional investors own 71.74% of the company's stock.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.